Platinum Priority – Kidney CancerEditorial by Jesus Garcia-Donas, Sandra Falagan and Juan Francisco Rodriguez-Moreno on pp. 640–641 of this issuePharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma
Introduction
The introduction of targeted therapy (TT) in the management of metastatic renal cell carcinoma (mRCC) has led to improved outcomes at the expense of side effects associated with treatment [1]. Since mRCC remains an incurable disease, quality of life (QoL) is an important consideration for patients. During the last decade, two different types of TT agents have been used for the treatment of mRCC: vascular endothelial growth factor-TT (VEGF-TT), mainly TKIs (tyrosine kinase inhibitors); and mTOR inhibitors. These drugs are generally well tolerated, but major toxicities frequently arise. Some series show that up to 50% of patients can develop grade ≥3 toxicities, and a significant number experience adverse events (AEs) leading to treatment interruption, dose reduction, and drug discontinuation [2]. Therefore, individual variability in drug efficacy resulting in therapeutic failure is an important issue. Identification of genomic variants may aid in the development of strategies for patient selection that could lead to improved adherence to treatment and better QoL. Moreover, pharmacogenomics may reduce costs and improve optimal drug development [3].
The mechanism underlying TT toxicity is complex and not entirely understood [4]. While fatigue/asthenia, rash, and diarrhea are common to both sunitinib and mTOR inhibitors, other AEs are class-specific [1], [2]. For example, sunitinib is associated with higher incidence of hypertension and hand-foot syndrome, while higher incidence of infections, pneumonitis, hypercholesterolemia, and hyperglycemia has been observed for mTOR inhibitors [2].
Clinical determinants of TT toxicity, such as age, female gender, and low body-surface area, only partly explain the interindividual variability in drug toxicity [5]. Patients with similar clinical characteristics may exhibit wide variability in tolerability for the same drug according to their genetic background [6]. Single-nucleotide polymorphisms (SNPs) in the pharmacokinetic (PK) and pharmacodynamic (PD) pathways for TT agents have been postulated as a complementary explanation for this heterogeneous toxicity [3]. Not all TTs in the same class have the same toxicity profiles, and SNPs may contribute to shape these differences [7]. Sunitinib and mTOR inhibitors are significantly metabolized by cytochrome P450 proteins, predominantly CYP3A4, leading to variation in serum concentrations of the drugs [8], [9]. Similarly, concentrations may differ according to polymorphisms in transporters such as ABCB1 [10]. Therefore, SNPs of genes involved in drug PK pathways affect the frequency and severity of drug toxicities in mRCC [11], [12]. However, no individual SNP is currently used as a risk factor for TT toxicity in mRCC.
The aim of our study was to assess the association between six SNPs in three core genes implicated in the metabolic and transport pathways for sunitinib and mTOR inhibitors and the risk of grade ≥3 AEs and class-specific AEs such as hypertension in the sunitinib cohort and pneumonitis in the mTOR inhibitor cohort.
Section snippets
Patients
The cohort comprised 221 mRCC patients who received at least one cycle (4 wk on treatment) of sunitinib or mTOR inhibitors as TT at the Dana-Farber/Harvard Cancer Center (DF/HCC) between January 2005 and December 2011 and for whom genotyping was successful. Patients were exclusively of Caucasian ethnicity to ensure no admixture due to ancestry [13]. All patients provided written informed consent. The institutional review board for DF/HCC approved the study. Clinical data were ascertained from
Results
DNA was extracted and successfully genotyped for 221 patients with mRCC who received either sunitinib (n = 159) or temsirolimus or everolimus as an mTOR inhibitor (n = 62). All patients were Caucasian, and 81% had clear-cell RCC (Table 1).
Discussion
We hypothesized that variability in drug toxicity has a heritable component. We interrogated inherited variants for key genes involved in drug metabolism to develop a genetic risk profile. An accurate profile could facilitate individualization of treatment and minimization of toxicity [15]. In our series, in line with published data, most mRCC patients receiving TT experienced side effects, and up to 50% developed grade ≥3 toxicity [16]. Since TT is a noncurative therapy for mRCC and QoL is an
Conclusions
We found a statistically significant association between CYP3A4 rs4646437 polymorphism and high-grade toxicity in patients treated with sunitinib, whereby patients with the AG variant experienced a lower number of high-grade AEs. Testing for associations between genetic polymorphisms and toxicity is feasible and could potentially guide clinicians in selecting optimal personalized therapies for their patients, rather than using a “one size fits all” approach. This is particularly important in
References (29)
- et al.
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Cancer Treat Rev
(2013) - et al.
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma
Eur Urol
(2015) - et al.
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
Lancet Oncol
(2013) - et al.
Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma
Clin Genitourin Cancer
(2015) - et al.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Lancet Oncol
(2011) - et al.
Targeted therapies for renal cell carcinoma: review of adverse event management strategies
J Natl Cancer Inst
(2012) Pharmacogenomics and drug toxicity
N Engl J Med
(2008)- et al.
Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms
Am J Roentgenol
(2013) - et al.
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
Br J Cancer
(2008) - et al.
Pharmacogenomics and individualized medicine: translating science into practice
Clin Pharmacol Ther
(2012)
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
Oncologist
In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors
Drug Metab Dispos
Clinical pharmacokinetics of everolimus
Clin Pharmacokinet
Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer
J Thyroid Res
Cited by (11)
CYP3A4 genetic variants are associated with susceptibility of non-small cell lung cancer in a Shaanxi Han population
2020, GenomicsCitation Excerpt :Rs4646437 was identified SNP in CYP3A4 association with cancer at previously published studies. For example, Guillermo et al. showed that rs4646437 was related to lower risk in patients with Metastatic Renal Cell Carcinoma [29]. The significantly decreased association was examined between rs4646437 and prostate cancer [30].
Genotyping the Host in the Battle Against Cancer
2016, European Urology FocusSunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
2020, Actas Urologicas EspanolasThree Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer
2023, Journal of Personalized MedicineMeta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
2021, Frontiers in Pharmacology